How can biomarkers become surrogate endpoints?

European Journal of Cancer, Supplement - Tập 5 - Trang 37-40 - 2007
B. Berns1, P. Démolis2, M.E. Scheulen3
1Clinical Haematology & Oncology, Centocor Ltd., 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, UK
2Assesment Anticancer Drugs, AFSSaPS, Saint Denis 143, 147 Boulevard Anatole France, F-93285 Saint-Denis Cedex, Paris, France
3Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstraße 55, D-45122 Essen, Germany

Tài liệu tham khảo